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The association of Brugada syndrome (BrS) and atrial
ﬁbrillation (AF) is well known, but its prognostic signiﬁ-
cance has not been well deﬁned.1 In 1992, the Brugada
brothers described 8 patients with a syndrome of ST segment
elevation in ECG leads V1–V3 associated with right bundle
branch block appearance and the risk of ventricular ﬁbrilla-
tion (VF) and sudden cardiac death.2 One patient was an
8-year-old girl with an additional history of paroxysmal AF.
She experienced her ﬁrst paroxysm of AF soon after birth,
while her ﬁrst episode of syncope occurred at 8 years of age.
Patients with a spontaneous type 1 ECG pattern, those with
inducibility of ventricular arrhythmias, or those who fulﬁlled
criteria for an implantable cardioverter have a higher
incidence of atrial arrhythmias, suggesting that atrial arrhyth-
mias may be considered as an indicator for more severe
disease.3 The recent HRS/EHRA expert consensus state-
ment4 does not recommend genetic testing for AF because of
the limited outcome data available. The most important
reason was that none of the current known disease-associated
genes for AF has been shown to account for 45% of the
disease. However, the possibility that within the large pool of
young patients with new-onset AF, a relatively large
minority with latent BrS may be at risk of sudden death (as
ﬁrst reported by our group5) could potentially increase the
diagnostic and prognostic contribution of genetic testing.
Recent observations from the Brugada group5–7 have sup-
ported the results of our seminal work, posing a new
challenge for all cardiologists in the management of patients
with AF. In our initial experience, this association was
analyzed in as many as 346 individuals with new-onset AFKEYWORDS Brugada syndrome; Atrial ﬁbrillation; Ventricular ﬁbrillation;
Sudden death; Flecainide
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lone AF and 11 with ECG Brugada pattern, all diagnosed as
having lone AF (5.7%). Of these, 3 patients developed BrS,
experiencing ventricular tachycardia (VT)/VF during follow-
up. Similarly, Junttila et al6 reviewed cases in which the
typical Brugada pattern was observed in the electrocardio-
gram after a range of trigger events (such as fever or
propofol). Of the 9 patients in whom BrS was detected after
administration of sodium-channel blockers, 1 had sudden
cardiac death and another VT. Recently, the Brugada group
has reported that AF was the ﬁrst clinical manifestation in 35
of 611 patients with BrS.7 Of these, 11 patients were found
after class IC antiarrhythmic drug therapy and 2 patients had
an acute arrhythmic event. The ﬁrst patient had an aborted
sudden death after starting propafenone; the second patient
was a 22-year-old woman who arrived at the emergency
room because of a ﬁbrillation episode and atrial ﬂutter. A few
minutes after administration of ﬂecainide, the patient showed
a type 1 ECG Brugada pattern with subsequent degeneration
into VF.7
We report here a rare additional case of a pathognomonic
association between AF and VF in a young patient with new-
onset lone AF and latent BrS, which further emphasizes the
prognostic importance of considering ﬂecainide testing in
such a selected patient population.
Case report
A 22-year-old man with lone AF presented with a 2-month
history of recurrent presyncopal episodes occurring at rest
and preceded by blurred vision and dizziness. In particular,
he had the feeling of being just about to lose consciousness
without complete loss. Symptoms were self-limiting, lasting
just a few seconds, and were not related to physical activity
or stress. The patient had no family history of heart disease,
sudden death, or recurrent syncope, and did not take any
medications before or after such episodes. At admission,
baseline ECG showed no abnormalities (Figure 1A) and
laboratory analysis, physical examination, and echocardiog-
raphy were normal. A subcutaneously implanted ECG
loop recorder did not show any atrial or ventricularpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Atrial ﬁbrillation (AF) can be the ﬁrst clinical
manifestation of latent Brugada syndrome (BrS).
 AF triggering ventricular ﬁbrillation and ventricular
ﬁbrillation triggering AF are 2 distinct clinical
manifestations sharing common genetic
mechanisms.
 Patients with new-onset lone AF and latent BrS may
be at risk of sudden death.
 Caution should be used in using intravenous
ﬂecainide to acutely treat paroxysmal AF in
patients with new-onset lone AF.
 Guideline recommendations for AF should include
ﬂecainide testing to identify patients with new-
onset lone AF and latent BrS to avoid potential
fatalities.
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monitoring. The patient underwent electrophysiologic test-
ing (EPT) and during electrophysiologic study ﬂecainide
infusion (2 mg/kg over 10 minutes) resulted in type 1 ECG
Brugada pattern (Figure 1B), which was followed by
concomitant development of VF and AF immediately after
programmed ventricular stimulation (Figure 2A). VF lasted 7
seconds, spontaneously reverting to AF (Figure 2B) and then
to normal sinus rhythm with a coved BrS ECG pattern
(Figure 3). After EPT, since the patient’s setting was
compatible with BrS, VT/VF inducibility, and a history of
recurrent presyncopal episodes, he received an implantable
cardioverter-deﬁbrillator (ICD) and after 8-month follow-up
remained asymptomatic. The patient had a positive SCN5A
genetic test while genetic screening of his family was
underway.Discussion
The actual prevalence of BrS is unknown. It is estimated to
affect around 5 in 10 000 individuals, but this ﬁgure is an
underestimate owing to the existence of concealed electro-
cardiographic forms,8,9 which can occasionally be unmaskedby fever or sodium-channel blocking drugs, as in our case.
Aborted sudden cardiac death is the ﬁrst manifestation of
BrS in 6%–21% of patients,10–13 and in 17%–31% of BrS
patients the diagnosis is made following etiologic study of
syncope, which is generally secondary to self-limited epi-
sodes of polymorphic VT,8–11 as in this patient. The case
presented here, a young male patient with lone AF who
exhibited coved-type ECG and VF under administration of
ﬂecainide, calls our attention to life-threatening risk because
a portion of such patients would manifest BrS and admin-
istration of class I antiarrhythmic drugs could yield devas-
tating results. Indeed, this case emphasizes that some patients
with new-onset lone paroxysmal AF having latent undiag-
nosed BrS can indeed be at risk of sudden death, because
intravenous ﬂecainide or class I antiarrhythmic drugs are
commonly used in AF patients without structural heart
disease to acutely treat episodes of paroxysmal AF, as in
our case. Of note, in our patient, immediately after ﬂecainide
testing VF and AF developed concomitantly, in all proba-
bility as a result of global atrial and ventricular vulnerability.
According to the latest consensus statement,14 this patient
would have been considered as a Class IIb recommendation
for ICD implantation (inducible VF, no spontaneous VT/VF
or syncope). Although he experienced “presyncopal” epi-
sodes without complete loss of consciousness like frank
syncope, EPT demonstrated ﬂecainide-induced type I BrS
ECG pattern and inducibility of transient, spontaneously
reverting VF before AF. Therefore, after EPT and both
ﬂecainide-induced coved BrS ECG pattern and inducibility
of VF, we considered the prognostic signiﬁcance of the
spontaneous presyncopal episodes to be equivalent to that of
frank syncope and then we decided to implant an ICD as a
therapeutic approach similar to that of BrS patients with
arrhythmic cardiac arrest. These ﬁndings, taken together,
emphasize the prognostic signiﬁcance of recurrent presyn-
copal episodes in young patients with lone AF potentially
having a latent BrS. Identiﬁcation of such selected patients is
crucial, since they should be managed with ICD implantation
and not with the use of sodium-channel blockers, which are
now widely used acutely or chronically to treat or prevent AF
recurrences. These ﬁndings also suggest revisiting current
guidelines on AF to include ﬂecainide/ajmaline testing in
selected patients with new-onset AF in daily clinical practice
to avoid fatalities.15
Figure 1 A: Baseline 12-lead ECG shows no abnormality. B: After ﬂecainide testing, a coved ST-segment elevation in leads V1–V2 compatible with a type I
Brugada syndrome ECG pattern was evident.
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Figure 2 Programmed ventricular stimulation resulted in concomitant development of ventricular ﬁbrillation (VF) and atrial ﬁbrillation (AF). VF lasted 7
seconds and spontaneously reverted to sustained AF. The paper speeds are as follows: A: 16 mm/s; B: 25 mm/s.
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Figure 3 Twelve-lead ECG after electrophysiologic testing showing a stable sinus rhythm with coved Brugada syndrome pattern.
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